Volume 12, Number 10—October 2006
Dispatch
Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa
Table 2
Mean adenovirus neutralizing antibody titers for positive samples
Origin | Mean VNA* titer ± standard deviation† |
|||
---|---|---|---|---|
AdHu5 | AdC68 | AdC6 | AdC1 | |
Humans, United States | 116 ± 111 | 40 ± 0 | 20 ± 0 | 20 ± 0 |
Humans, Thailand | 303 ± 353‡ | 20 ± 0 | 80 ± 44 | 33 ± 25 |
Humans, Cameroon | 125 ± 114 | 109 ± 145 | 82 ± 52‡ | 58 ± 41 |
Humans, Côte d'Ivoire | 162 ± 212 | 60 ± 51‡ | 37 ± 34‡ | 148 ± 275 |
Humans, Nigeria | 165 ± 206 | 29 ± 20 | 80 ± 115‡ | 42 ± 23 |
Chimpanzees, United States | 164 ± 233 | 201 ± 204 | 137 ± 160 | 64 ± 72 |
*VNA , virus neutralizing antibody.
†p values were determined by a Student t test to assess differences between titers in experimental samples and control samples. Human sera from the United States were used as a reference for antibodies to AdHu5, and chimpanzee sera were used as a reference for titers to AdC68, AdC6, and AdC1. Experimental samples in which >10 samples were positive for the given adenovirus are shown in boldface.
‡Samples that showed a statistically significant difference (p<0.05).